PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1447058
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1447058
Small Molecule Targeted Cancer Therapy Market Forecasts to 2030 - Global Analysis By Type, Application and By Geography
According to Stratistics MRC, the Global Small Molecule Targeted Cancer Therapy Market is accounted for $82.5 billion in 2023 and is expected to reach $147.9 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Small molecule drugs can penetrate cells more easily than larger molecules, allowing them to effectively inhibit the activity of proteins and enzymes critical for cancer cell survival.
It refers to the segment of the pharmaceutical industry dedicated to developing and commercializing drugs specifically designed to target and inhibit the growth of cancer cells through small molecules. These therapies work by interfering with specific molecules involved in the growth, progression, and spread of cancer, thereby offering more precise and targeted treatment options compared to traditional chemotherapy.
According to the FDA, the half life of monoclonal antibodies like cetuximab (3.1-7.8 days) is much longer than those of small-molecule agents like gefitinib (48 hours).
Market Dynamics:
Driver:
Increasing incidence of cancer
With cancer rates on the rise across various demographics and geographies, there is a growing demand for effective treatment options. Small molecule targeted therapies offer promising avenues for cancer treatment by specifically targeting molecular alterations in cancer cells, thereby inhibiting their growth or inducing cell death with minimal harm to healthy cells. Additionally, as traditional treatments like chemotherapy often come with debilitating side effects, the demand for more targeted and less toxic therapies is increasing.
Restraint:
High development costs
Developing small molecule drugs tailored to target specific cancer cells involves extensive research, clinical trials, and regulatory approvals, all of which incur substantial expenses. The intricate process of identifying suitable molecular targets, designing compounds, optimizing their efficacy, and ensuring their safety demands substantial financial investments. However, the rigorous regulatory requirements and lengthy approval timelines further escalate the overall development costs. For smaller biotechnology companies or startups with limited financial resources, these high costs present a considerable barrier to entry into the market.
Opportunity:
Technological advancements
Cutting-edge technologies such as high-throughput screening, molecular modeling, and computational chemistry enable the identification and design of small molecules with enhanced specificity and efficacy against cancer targets. Advances in analytical techniques facilitate the precise characterization of drug candidates, optimizing their pharmacokinetic and pharmacodynamic properties. Moreover, innovations in drug delivery systems, including nanotechnology and targeted drug delivery, enhance the therapeutic index of small molecule drugs by improving their tumor penetration and reducing off-target effects.
Threat:
Limited biomarkers
Biomarkers, which are measurable indicators of biological processes or responses to treatment, play a crucial role in identifying suitable patients for targeted therapies. The availability of biomarkers specific to certain types of cancer or targeted therapies is often limited. This limitation hampers the precise selection of patients who would benefit most from small molecule targeted therapies, leading to suboptimal treatment outcomes and potentially limiting market growth. Therefore, the lack of biomarkers limits the efficacy of targeted cancer medicines and also prevents market growth by reducing the number of patients that are eligible for these treatments.
Covid-19 Impact:
Disruptions in healthcare services and resources diverted attention and resources away from cancer treatment, leading to delays in diagnosis and initiation of therapy. Clinical trials for new small molecule targeted therapies faced interruptions or postponements, hindering the development and approval of new drugs. Supply chain disruptions and restrictions on movement further affected the manufacturing and distribution of existing therapies, causing shortages and delays in treatment access for patients. However, financial strains on healthcare systems and patients also impacted the affordability and utilization of these therapies.
The tyrosine kinase inhibitors segment is expected to be the largest during the forecast period
Due to their unique mechanism of action and effectiveness in treating various types of cancers. These inhibitors target specific tyrosine kinases, which are enzymes that play a crucial role in the signaling pathways involved in cancer cell growth and proliferation, Tyrosine Kinase Inhibitors segment is expected to hold the largest share during the projection period. Their precision targeting minimizes damage to healthy cells, leading to fewer adverse effects compared to traditional chemotherapy. Additionally, the development of novel TKIs with improved efficacy and reduced toxicity profiles has expanded treatment options for patients with different types of cancers, further driving market growth.
The melanoma segment is expected to have the highest CAGR during the forecast period
Melanoma segment is estimated to have the considerable growth over the forecast period. Melanoma, a type of skin cancer, has seen a substantial rise in incidence globally, driving the demand for effective treatments. Small molecule targeted therapies offer precision in combating melanoma by specifically targeting molecules involved in cancer growth and progression, resulting in enhanced efficacy and reduced side effects compared to traditional treatments. Additionally, advancements in research have led to the development of novel small molecule drugs tailored to target specific genetic mutations and pathways implicated in melanoma, expanding the therapeutic options available to patients. These elements are enhancing the segmental growth.
Region with largest share:
Because treatments for cancer are increasingly being customized to a patient's unique molecular profile, a phenomenon recognized as personalized medicine, the Asia Pacific region is expected to hold the largest share of the market during the projected period. Targeting specific small molecules in cancer patients may allow for more individualized and accurate treatment plans that take into account the particulars of their individual cases. As genome sequencing technology develops, it becomes simpler to find uncommon genetic anomalies and biomarkers connected to certain cancers. Furthermore, pharmaceutical companies can create highly targeted medications that are linked to certain genetic profiles due to the wealth of genetic data available in the area, improving treatment efficacy and precision.
Region with highest CAGR:
As healthcare providers become more knowledgeable about the benefits and effectiveness of targeted therapy in cancer treatment, they are more likely to recommend it to their patients, Asia Pacific region is estimated to witness profitable growth throughout the extrapolated period. This awareness leads to greater adoption of small molecule targeted therapies, which are designed to specifically target cancer cells while minimizing damage to healthy cells. Additionally, as healthcare providers in the region stay updated on the latest advancements and clinical evidence supporting targeted therapies, they become better equipped to identify suitable patients for these treatments and tailor therapy regimens to individual needs.
Key players in the market
Some of the key players in Small Molecule Targeted Cancer Therapy market include Abbott Laboratories, Amgen, AstraZeneca, Bayer HealthCare AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cytokinetics Inc, Genentech, GlaxoSmithKline plc, Hospira Inc and Novartis.
Key Developments:
In February 2024, Novartis to acquire cancer-centric MorphoSys for $2.9 bln. Novartis will offer shareholders 68.00 euros per share in cash and take MorphoSys private after the deal, which is contingent on certain conditions, including a minimum acceptance threshold of 65% of MorphoSys' share capital and regulatory clearances.
In February 2024, Erasca, Inc., a precision oncology company, has entered into clinical trial collaboration and supply agreements with pharmaceutical giant Novartis to advance the development of a new cancer treatment.
Types Covered:
- Tyrosine Kinase Inhibitors
- Small Molecule Drug Conjugates
- Other Types
Applications Covered:
- Breast Cancer
- Multiple Myeloma
- Melanoma
- Lymphoma
- Prostate Cancer
- Other Applications
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Small Molecule Targeted Cancer Therapy Market, By Type
- 5.1 Introduction
- 5.2 Tyrosine Kinase Inhibitors
- 5.3 Small Molecule Drug Conjugates
- 5.4 Other Types
6 Global Small Molecule Targeted Cancer Therapy Market, By Application
- 6.1 Introduction
- 6.2 Breast Cancer
- 6.3 Multiple Myeloma
- 6.4 Melanoma
- 6.5 Lymphoma
- 6.6 Prostate Cancer
- 6.7 Other Applications
7 Global Small Molecule Targeted Cancer Therapy Market, By Geography
- 7.1 Introduction
- 7.2 North America
- 7.2.1 US
- 7.2.2 Canada
- 7.2.3 Mexico
- 7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 Italy
- 7.3.4 France
- 7.3.5 Spain
- 7.3.6 Rest of Europe
- 7.4 Asia Pacific
- 7.4.1 Japan
- 7.4.2 China
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 New Zealand
- 7.4.6 South Korea
- 7.4.7 Rest of Asia Pacific
- 7.5 South America
- 7.5.1 Argentina
- 7.5.2 Brazil
- 7.5.3 Chile
- 7.5.4 Rest of South America
- 7.6 Middle East & Africa
- 7.6.1 Saudi Arabia
- 7.6.2 UAE
- 7.6.3 Qatar
- 7.6.4 South Africa
- 7.6.5 Rest of Middle East & Africa
8 Key Developments
- 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 8.2 Acquisitions & Mergers
- 8.3 New Product Launch
- 8.4 Expansions
- 8.5 Other Key Strategies
9 Company Profiling
- 9.1 Abbott Laboratories
- 9.2 Amgen
- 9.3 AstraZeneca
- 9.4 Bayer HealthCare AG
- 9.5 Boehringer Ingelheim GmbH
- 9.6 Bristol-Myers Squibb
- 9.7 Cytokinetics Inc
- 9.8 Genentech
- 9.9 GlaxoSmithKline plc
- 9.10 Hospira Inc
- 9.11 Novartis
List of Tables
- Table 1 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
- Table 3 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
- Table 4 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
- Table 5 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
- Table 6 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
- Table 7 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 8 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
- Table 9 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
- Table 10 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
- Table 11 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 12 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 13 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
- Table 14 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
- Table 15 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
- Table 16 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
- Table 17 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
- Table 18 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
- Table 19 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 20 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
- Table 21 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
- Table 22 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
- Table 23 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 24 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 25 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
- Table 26 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
- Table 27 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
- Table 28 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
- Table 29 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
- Table 30 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
- Table 31 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 32 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
- Table 33 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
- Table 34 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
- Table 35 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 36 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 37 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
- Table 38 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
- Table 39 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
- Table 40 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
- Table 41 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
- Table 42 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
- Table 43 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 44 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
- Table 45 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
- Table 46 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
- Table 47 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 48 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 49 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
- Table 50 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
- Table 51 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
- Table 52 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
- Table 53 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
- Table 54 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
- Table 55 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 56 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
- Table 57 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
- Table 58 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
- Table 59 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 60 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 61 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
- Table 62 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
- Table 63 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
- Table 64 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
- Table 65 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
- Table 66 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
- Table 67 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 68 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
- Table 69 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
- Table 70 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
- Table 71 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 72 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
